This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 8, 2005
Last updated: May 29, 2017
Last verified: May 2017
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes). Asenapine is an investigational medication for the treatment of manic or mixed episodes of bipolar disorder. This is a 3-week study that will test the safety and efficacy of this medication. Patients will receive either asenapine, olanzapine (a medication that is already approved for the treatment of bipolar mania), or placebo (no active medication). Patients will be required to stay in the hospital for at least the first seven days of treatment. Patients that complete the 3 week study may be eligible to continue in extension studies for an additional 9 (study A7501006) to 49 (study A7501007) weeks.

Condition Intervention Phase
Bipolar Disorder Drug: Asenapine Drug: Olanzapine Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) [ Time Frame: The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 ]

Secondary Outcome Measures:
  • Ratings on the Clinical Global Impression scale in which severity and improvement of mania, depression, and overall bipolar state are rated. [ Time Frame: The CGI assessment at days 1,7 and endpoint (day 21 or the time of the last assessment). ]
  • The PANSS (Positive and Negative Symptom Scale) was used to assess psychotic symptoms [ Time Frame: The PANSS was administered at Days 1, 7 and 21(or the time of the last assessment). ]
  • The MADRS (Montgomery Asberg Depression Rating Scale) was used to assess depressive symptoms [ Time Frame: The MADRS was administered on Days 1, 7 and 21(or at the time of the last assessment).l ]
  • The Readiness for Discharge Questionaire (RDQ) was administered to characterize the subject's readiness for discharge. The investigator was to make the decision about discharging the subject. [ Time Frame: The RDQ was administered on Day 1, 2, 4, 7 , 14 and 21 (or at the time of the last assessment) ]
  • CogState, cognition battery, was used to assess changes in cognition [ Time Frame: Cog State was administered at screening, Day 1 (baseline) and Days 7, 14, 21 (or endpoint). ]
  • SF (short form)-36 and TSQM (Treatment Satisfaction Questionnaire for Medication) -- 2 measures of Quality of Life were administered. [ Time Frame: The SF Health Survey was administered at Day 1 and Day 21 or endpoint. The TSMQ was administered at Day 21 or endpoint.. ]
  • The SARS (Simpson Angus Rating Scale); the AIMS (Involuntary Movement Scale and the BARS (Barnes Akathisia Scale) were used to assess extrapyramidal symptoms [ Time Frame: The SARS, AIMS and BARS assessments were administered at Days 1, 7 and 21 or endpoint. ]
  • Concomitant medication use was recorded [ Time Frame: Concomitant medication use was recorded whenever it occurred ]
  • Physical examination, laboratory and electrocardiogram findings and weight/abdominal girth and vital signs were recorded. [ Time Frame: Physical exam, ECG, laboratory and weight were recorded at screening and Day 21 or endpoint. Laboratory work was also done at baseline. ]
  • Adverse events (AEs) [ Time Frame: AEs were recorded whenever they occurred.. ]
  • Pharmacokinetic analysis was done to determine the level of the drug in the blood [ Time Frame: Pk samples were taken at Day 1, 7, 14 and 21 (or endpoint). ]

Enrollment: 488
Actual Study Start Date: November 30, 2004
Study Completion Date: April 29, 2006
Primary Completion Date: April 29, 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1
Drug: Asenapine
Asenapine, 3 weeks
Other Name: Org 5222
Active Comparator: Arm 2
Drug: Olanzapine
Olanzapine, 3 weeks
Placebo Comparator: Arm 3
Drug: Placebo
placebo, 3 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a DSMIV diagnosis of bipolar I disorder, current episode manic or mixed.

Exclusion Criteria:

  • Patients with unstable medical conditions or clinically significant laboratory abnormalities or patients who are rapid cyclers (ie. have had 4 or more (including current) mood episodes in the past 12 months); have any other psychiatric disorder other than bipolar I disorder as a primary diagnosis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Study Data/Documents: CSR Synopsis  This link exits the site

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00159744     History of Changes
Other Study ID Numbers: P07008
A7501004 ( Other Identifier: Schering-Plough )
Study First Received: September 8, 2005
Last Updated: May 29, 2017

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents processed this record on September 20, 2017